MCB-22-174
Based on 1 Customer Validation
MCB-22-174 is a deuterated Piezo1 agonist, with an EC50 value of 6.28 μM. MCB-22-174 remarkably activates the CaMKII/ERK signaling pathway and initiates Ca2+ influx in rMSCs. MCB-22-174 significantly decreases the expression of chondrogenesis markers (Comp, Acan) and adipogenesis markers (Lpl, Fabp4) in MSCs. MCB-22-174 can effectively improve bone quality in hind-limb unloading (HU) model rats. MCB-22-174 can be used for the study of disuse osteoporosis (OP).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.78%
- CAS No.: 3058199-58-6
- Formule: C16H14DCl2N5OS2
- Masse moléculaire:429.37
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
In Vitro
MCB-22-174 (0-40 μM) exhibits potent agonistic activity on Piezo1 in C3H10T1/2 cells with an EC50 value of 6.28 μM[1].
MCB-22-174 (3-5 μM, 72 h) significantly upregulates the mRNA level of Runx2 in rMSCs and promotes osteogenesis more effectively than Yoda1 (HY-18723)[1].
MCB-22-174 (5 μM, 5-15 min) remarkably upregulates p-ERK and p-CaMKII in rMSCs, and activates the CaMKII/ERK signaling pathway more efficiently than Yoda1[1].
MCB-22-174 (5 μM) significantly decreases the expression of chondrogenesis markers (Comp, Acan) and adipogenesis markers (Lpl, Fabp4) in MSCs, showing a more significant suppression of chondrogenesis and adipogenesis than Yoda1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SD rats (2-month-old) were subjected to hind-limb unloading by tail suspension, with their tails fixed on the upper lids of cages to detach the hind limbs from the ground (forelimbs unaffected), simulating weightlessness to induce disuse osteoporosis[1]
-
Dosage:2 mg/kg (5 μmol/kg)
-
Administration:Intraperitoneally injected on days 1, 4, 7, 10, and 13
-
Result:Improved bone quality in HU model rats.
Upregulated bone volume ratio (BV/TV) and trabecular thickness (Tb.Th.).
Downregulated trabecular separation (Tb.Sp.).
Increased the fluorescent area of alkaline phosphatase (ALP).
Promoted osteogenesis, with better efficacy than Yoda1.
Application
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 3058199-58-6
-
Unlabeled CAS 3087134-90-2
-
Appearance Solid
-
Masse moléculaire 429.37
-
Formule C16H14DCl2N5OS2
-
Color Off-white to light yellow
-
SMILES
ClC(C=CC=C1Cl)=C1C([2H])SC2=NN=C(C3=NC=C(NC[C@H](O)C)N=C3)S2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Pureté et documentation
-
Fiche technique (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
MCB-22-174 Related Classifications
HY-165607S Related Classifications
Powered by Bioz